Specialty Pharma Launches With Purchase Of Rocaltrol From Roche
This article was originally published in The Pink Sheet Daily
Executive Summary
Fontus’ “buy and build” strategy will focus on gaining and marketing established nephrology, endocrinology and acute-care drugs.
You may also be interested in...
FDA Convenes Panel To Review Drug-Associated Suicidality Study
FDA joint committee meets July 10 to consider results of placebo-controlled trials of 11 drugs, including Lamictal, Carbatrol and Lyrica.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.